|
PARTNERING
|
Korea Brain Research Institute
|
(T1)Repurposing Ibrutinib and Abemaciclib: Therapeutic Effects in Alzheimer’s Disease, (T2)Composition for Preventing and Treating Diseases Related to TDP-43
|
H60
|
|
KOREA LIFE SCIENCE
|
Korea Corporation Security
|
GxP Solution, Computer Software Assurance, CSV Service
|
F51
|
|
KOREA LIFE SCIENCE
|
Korea Drug Research Association
|
Promotion of Demand-Driven Strategic Programs for an R&D-Centered Pharmaceutical Industry
|
E36
|
|
PARTNERING
|
Korea Institute of Science and Technology
|
Compositions for preventing or treating allergic disease comprising extracts of Asiasarum sieboldi, Platycodon grandiflorum and Cinnamomum cassia
|
H60
|
|
NextRegenX
|
Korea national institute for bioethics policy
|
Support program for public IRB specializing in regenerative medicine
|
C22
|
|
KOREA LIFE SCIENCE
|
Korea Safety Equipment Association
|
Bio-Health Occupational Safety Pavilion
|
G35
|
|
KOREA LAB Autumn
|
KORINSTECH
|
Gel Hardness Tester, Tablet Hardness Tester, Leak Tester, Micro Leak Tester
|
F12
|
|
PARTNERING
|
Liberi-CCubeLab Inc.
|
Liberi-CCubeLab is a global licensing & BD consulting firm specializing in the pharmaceutical and bio sectors. It is a joint venture between Liberi Group (global leading L&BD consulting firm in Europe) and C Cube Lab (leading biotech business consulting firm in Korea). This JV was launched by combining the capabilities of both companies to enhance and maximize the performance of global licensing and co-development advisory services for Korean bio companies. We provide professional consulting services for implementing global licensing-out, co-development, and investment attraction, by combining Liberi Group’s extensive global L&BD success experience with C Cube Lab’s domestic and international expertise in business strategy, market research, and business deals in the bio sector.
|
C60
|
|
PARTNERING
|
Liflex Science Inc
|
We aim to develop an oligonucleotide cartilage regeneration injection targeting miR-204, a key factor in the development of degenerative arthritis. Specifically, we have identified a target pathogenic factor that not only prevents disease progression but also induces cartilage regeneration. Furthermore, we have identified a substance that effectively inhibits this pathogenic factor and are conducting efficacy and toxicity testing.
|
A60
|
|
NextRegenX
|
Live Cell Instrument Co., Ltd.
|
Cell Culture Support Systems
|
B25
|
KYUNGYON EXHIBITION CORP.